Fox Run Management, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 11,788 shares of AMLX stock, worth $38,900. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,788Holding current value
$38,900% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding AMLX
# of Institutions
142Shares Held
49.1MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$22.4 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$15.3 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$8.89 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$8.81 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$8.01 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $193M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...